A warm, non-judgmental space to learn about psychedelic-assisted therapies — how they work, how to prepare, and how to integrate the experience for lasting transformation.
Whether you just heard about psychedelic therapy for the first time or you're actively looking for a provider, this is where to begin. We've organized everything by topic so you can go at your own pace, in your own order.
No jargon. No judgment. No pressure. Just honest, evidence-based information to help you decide if this path is right for you.
Explore the medicines →A plain-language overview of the substances used in therapeutic settings — their history, mechanisms, and why the medical community has renewed its interest after decades of prohibition. A great place to start if you're new.
From serotonin receptors to the default mode network — the neuroscience of why psychedelics produce such profound shifts in consciousness and emotion.
What randomized controlled trials actually show — depression, PTSD, addiction, end-of-life anxiety. We cite the studies so you can read them yourself.
Set and setting, medication interactions, dietary guidelines, how to choose a guide, and how to emotionally ready yourself.
The work that happens after the session is often where the most lasting change occurs. Learn what integration is, why it matters, and how to do it well.
What's currently legal, what's changing, where to find legal options in the US and abroad, and how to stay safe and informed.
An honest look at what the risks actually are, who should approach with caution, drug interactions, and the harm reduction principles that protect people.
What credentials to look for, the right questions to ask, red flags that signal an unethical provider, and directories of vetted practitioners.
What different treatments cost, what insurance covers (and doesn't), sliding-scale options, clinical trials, and scholarship programs.
Psychedelic use predates written history. From Amazonian ayahuasca ceremonies to Albert Hofmann's accidental 1943 LSD synthesis, to the Harvard Psilocybin Project, to the War on Drugs shutdown — and now to FDA Breakthrough Therapy designations. Understanding this arc helps make sense of where we are today.
Conventional antidepressants manage symptoms by adjusting neurotransmitter levels. Psychedelics appear to work differently — by temporarily quieting the default mode network (the brain's "self-referential" system) and promoting neuroplasticity, they may allow the brain to break out of entrenched depressive patterns entirely.
Psychedelic therapy is not simply taking a drug — it's a structured therapeutic process. In clinical settings, a single psilocybin or MDMA session is typically surrounded by multiple preparation meetings and integration sessions. Understanding the full arc helps participants get more from the experience.
The window of neuroplasticity following a psychedelic experience — sometimes called the "critical period" — is real and time-limited. Research suggests that active integration practices during this window can dramatically improve long-term outcomes. Learn what the evidence says about journaling, therapy, and somatic work.
If you're not sure where to begin, these five steps will give you a solid foundation — in about an hour of reading.
Each medicine has a unique profile, mechanism, history, and therapeutic context. Click any card to learn more — or scroll down for a side-by-side comparison.
Derived from 200+ mushroom species, psilocybin converts to psilocin in the body — a serotonin 2A agonist that dramatically reduces default mode network activity. This quieting of the brain's "ego center" produces the characteristic dissolution of self, mystical states, and emotional release that underpin its therapeutic effects.
Unlike classic psychedelics, MDMA is an empathogen — it doesn't produce hallucinations but floods the brain with serotonin, dopamine, and oxytocin. This chemical cocktail reduces amygdala reactivity (the fear center), increases feelings of trust and empathy, and allows trauma memories to be revisited without overwhelming distress.
The most accessible psychedelic-adjacent therapy available today. An NMDA receptor antagonist with rapid antidepressant effects — often within hours of infusion — ketamine is particularly valuable for suicidal ideation and treatment-resistant depression where waiting weeks for an antidepressant to work isn't an option.
A brew combining the DMT-containing Psychotria viridis leaf with the MAOI-containing Banisteriopsis caapi vine — a combination that indigenous Amazonian healers discovered millennia ago. The MAOI makes orally-ingested DMT active, producing an intense, often purging experience with powerful therapeutic and spiritual dimensions.
Synthesized by Albert Hofmann at Sandoz in 1938 and discovered to be psychoactive in 1943, LSD was the original psychiatric psychedelic — studied extensively in the 1950s–60s before prohibition. It's now re-entering formal research, with trials at University of Basel, Imperial College, and others showing promise for anxiety and cluster headaches.
A powerful alkaloid from the Central African iboga shrub, used in Bwiti initiation ceremonies. It has produced dramatic results for opioid addiction — a single session appears to eliminate physical withdrawal symptoms and reset opioid tolerance — drawing intense interest despite serious cardiac risks that require careful medical screening.
All information is educational and based on current research. Consult a qualified provider before any treatment decisions.
| Medicine | Duration | Legal (US) | Best Evidence For | Experience Type | Intensity |
|---|---|---|---|---|---|
| Psilocybin | 4–6 hrs | Limited states | Depression, addiction, anxiety | Classic psychedelic | |
| MDMA | 6–8 hrs | Research only | PTSD, trauma | Empathogen | |
| Ketamine | 1–2 hrs | Legal | Depression, suicidality | Dissociative | |
| Ayahuasca | 6–12 hrs | Religious exemption | Depression, addiction | Classic psychedelic | |
| LSD | 8–12 hrs | Research only | Anxiety, cluster headaches | Classic psychedelic | |
| Ibogaine | 18–36 hrs | International clinics | Opioid addiction, PTSD | Dissociative / visionary |
Preparation is not just logistics — it's the first act of healing. The quality of your preparation directly shapes the quality of your experience and its lasting effects.
Psychedelic experiences can surface deep emotions, memories, and insights. Preparing your inner landscape is just as important as any logistical planning. The quality of your inner world going in shapes what the medicine can offer.
Your body is the vessel for your experience. How well you've cared for it in the days before directly affects comfort, openness, and the medicine's efficacy.
"Set" (mindset) and "setting" (environment) are perhaps the most important predictors of psychedelic experience quality — even more than dose. Timothy Leary identified this in the 1960s, and every researcher since has confirmed it.
The therapeutic relationship is one of the strongest predictors of outcomes. A skilled, ethical guide can transform a challenging experience into a healing one — and an unqualified or unethical one can cause real harm. Choose wisely.
An intention is not a demand, a script, or a goal — it's a direction of the heart, an honest question held with openness. The difference between "Fix my anxiety" and "Help me understand what my anxiety is protecting" is the difference between grasping and receiving.
You've prepared well. Now it's time to let go of preparation and simply be present. These principles, drawn from clinical research and decades of therapeutic experience, can help you navigate whatever arises.
Psychedelic therapy is not appropriate for everyone, and a reputable provider will conduct thorough screening. This is not meant to discourage — it's meant to ensure that if and when you do this work, it's done safely and at the right time.
Many conditions that appear on contraindication lists can still be navigated with the right medicine, the right provider, and the right level of monitoring. A thorough evaluation by a psychiatrist or physician with psychedelic expertise — not a general practitioner — is the appropriate standard. Don't self-screen yourself out of a potentially life-changing treatment without professional guidance.
Integration is the deliberate process of weaving what emerged in your session into the fabric of daily life. Without it, even the most profound experiences tend to fade within weeks. With it, a single session can become a turning point that reshapes who you are.
Neuroscience suggests that psychedelics create a temporary "critical period" of heightened neuroplasticity — the same state the brain is in during early childhood, when new patterns form most easily. This window typically lasts 2–4 weeks after a session.
How you use this window — whether you consciously engage with what arose, change behaviors, and build new habits — determines how much of the experience's potential becomes permanent change. Integration is the work that makes the medicine stick.
Free-write without censorship for 10–20 minutes daily in the first two weeks. Ask: What am I noticing in my body? What patterns are becoming clearer? What is the experience asking me to change? Return to your session notes — meaning often deepens over time.
The body often holds what the mind hasn't yet processed. Integration that stays purely cognitive tends to be shallow. Yoga, breathwork, dance, cold exposure, and massage can access and release material stored in the nervous system and musculature.
An integration therapist helps you make sense of what arose in a non-judgmental space, identify which insights are most clinically significant, and build a plan for acting on them. Look for therapists trained through MAPS, Fluence, or the Psychedelic Support network.
Not all insights are equally important — and some of the most important take time to recognize. Keeping a dedicated record of specific insights, what area of life they relate to, and whether they've been acted on helps you stay accountable to what the experience revealed.
There is something uniquely powerful about sharing your experience with others who understand the terrain. Peer integration circles — in-person or virtual — offer reflection, accountability, and the normalizing effect of knowing others have gone through similar territory.
Psychedelic experiences are often deeply personal and can be hard to articulate. Decide intentionally who you share with and how much. Some insights are strengthened by sharing; others need more time to solidify before they're spoken. Close friends, partners, or a therapist are often safer than broad sharing.
Some people experience a difficult integration period — prolonged anxiety, grief, re-emergence of trauma, or a feeling of groundlessness. This is more common than it's often acknowledged. It doesn't mean something went wrong — it often means significant material is being processed. But it does mean you need support.
The Fireside Project offers free peer support by phone and text specifically for people navigating difficult psychedelic experiences. The Zendo Project provides harm reduction guides. If you're in genuine crisis, please reach out to a mental health professional or call 988 (Suicide & Crisis Lifeline).
Psychedelic research is producing some of the most compelling results in modern psychiatry. These aren't fringe studies — they're randomized controlled trials published in the world's top journals. Here's what the evidence actually says.
Imperial College London's landmark RCT directly compared psilocybin therapy to a leading SSRI antidepressant over 6 weeks. Both groups showed similar reductions in depression scores — but psilocybin participants showed significantly greater improvements in emotional functioning, wellbeing, and the ability to feel pleasure. The study didn't prove psilocybin is "better," but it demonstrated comparable efficacy with a fundamentally different therapeutic profile.
The MAPS Phase 3 trial enrolled 90 participants with chronic PTSD — many with conditions severe enough to have failed multiple prior treatments. After three MDMA sessions with accompanying therapy, 67% of MDMA participants no longer met diagnostic criteria for PTSD, compared to 32% in the placebo group. 88% showed clinically significant improvement. These results, in a traditionally treatment-resistant population, represent some of the most dramatic outcomes in the history of psychiatric research.
NYU's randomized double-blind trial tested psilocybin therapy for alcohol use disorder — one of the most challenging addictions to treat. Participants who received psilocybin showed an 83% reduction in heavy drinking days at the 8-month follow-up, compared to 51% in the active control group. The study also found psilocybin was especially effective for participants who reported a mystical-type experience during their session.
Johns Hopkins researchers treated 24 adults with long-standing major depressive disorder — average illness duration of 17 years — with two psilocybin sessions plus supportive psychotherapy. At the 1-month follow-up, 71% showed greater than 50% reduction in depression symptoms. 54% met criteria for remission. At the 12-month follow-up, approximately half maintained the remission. For a condition that had failed to respond to conventional treatments for over a decade in many patients, these numbers are remarkable.
A Stanford Medicine study examined 30 special operations veterans who had received ibogaine treatment in Mexico. At the one-month follow-up, participants showed a 88% reduction in PTSD symptoms, 87% reduction in depression, and 81% reduction in anxiety — changes that were sustained at the 1-month follow-up. Many participants also reported improvements in traumatic brain injury symptoms that are notoriously unresponsive to conventional treatment. The findings prompted calls for US trials.
UC Davis researchers found that psychedelics — including psilocybin, DMT, and LSD — promoted the growth of dendritic spines and synaptic connections in cortical neurons, even at sub-psychedelic doses. This structural neuroplasticity occurred rapidly and persisted for at least a month. The findings help explain why psychedelics can produce lasting therapeutic effects from a small number of exposures, in contrast to daily medications that must be taken continuously.
Many of these studies have small sample sizes and methodological limitations — it's difficult to conduct a true double-blind trial with psychedelics. But the effect sizes are unusually large, the findings replicate across labs and countries, and the biological mechanisms are increasingly well-understood. The consensus among researchers is that the signal is real. The work now is to refine it.
These are composite accounts drawn from documented clinical trial testimonials, published memoirs, and harm reduction interviews. Names and details have been changed. They represent common experiences — not universal ones.
"I had been on six different antidepressants over fifteen years. Not one of them made me feel like myself. After the session, something had shifted — I could feel again. Not euphoria. Just… presence."
"MDMA didn't make me forget what happened. It let me remember it without being destroyed by it. I could look at those memories and feel compassion for the child I was — not just terror."
"I'd tried AA four times, rehab twice. The psilocybin session didn't lecture me about drinking. It showed me why I was drinking. I saw my father, myself at 12, and something just… unlocked."
"The ketamine clinic was the first legal option I could actually access and afford through insurance. It's not the deep spiritual experience others describe — but my nervous system finally has an off switch now. That's everything."
"I was terrified of dying — not the pain, but the disappearing. After the session, that terror was gone. I still don't know what happens when we die. But I'm no longer afraid to find out."
"I went to Mexico on a Thursday in withdrawal. By Saturday morning I was sitting outside eating eggs. I'd tried suboxone, methadone, cold turkey — nothing came close to what ibogaine did to the withdrawal. It was like it had been surgically removed."
Stories are the most powerful way to help others feel less alone in this decision. If you've had a psychedelic therapy experience — positive, difficult, or somewhere in between — we'd love to hear from you. All submissions are reviewed, kept confidential, and published only with your permission.
No question is too basic or too sensitive. We've organized the most common questions by topic — safety, legality, the experience itself, finding care, and cost. Click any question to read the answer.
Subscribe to our newsletter — we answer reader questions in every issue, and we read everything we receive.
Ask your question →This website is for educational and informational purposes only. Nothing on this site constitutes medical advice, and this site does not endorse or encourage any illegal activity. Psychedelic substances are controlled substances in most jurisdictions. Always consult a qualified healthcare professional before making decisions about your health and always act within the legal framework of your jurisdiction.